AVEO Pharmaceuticals Inc (AVEO):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】AVEO Pharmaceuticals Inc (AVEO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C9815)・商品コード:DATA904C9815
・発行会社(調査会社):GlobalData
・発行日:2018年11月
・ページ数:62
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
AVEO Pharmaceuticals Inc (AVEO) is a biopharmaceutical company which focuses on the discovery, development and commercialization of drugs for the treatment of various types of cancers. Its proprietary platform delivers insights into cancer and related diseases. AVEO develops its lead candidate tivozanib in North America as a treatment for renal cell carcinoma and other cancers. The company has strategic partnerships with EUSA, Novartis, Pharmstandard Group, Ophthotech Corporation, Biodesix Kyowa Hakko Kirin; Astellas Pharma, Biogen Idec International GmbH and others. AVEO is headquartered in Cambridge, Massachusetts, the US.

AVEO Pharmaceuticals Inc (AVEO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
AVEO Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
AVEO Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
AVEO Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
AVEO Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
AVEO Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
AVEO Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Aveo Pharma Amends Agreement With Biodesix For Ficlatuzumab 12
Aveo To Enter Into Co-Development Agreement For Lung Cancer Drug 14
National Comprehensive Cancer Enters Into Co-Development Agreement With AVEO Pharma And Astellas Pharma 15
Licensing Agreements 17
CANbridge Life Sciences Enters into Licensing Agreement with AVEO Oncology 17
EUSA Pharma Exercises Option for Licensing Agreement with AVEO Pharma for TiNivo Combination Study 19
Novartis to Terminate Licensing Agreement with Aveo Pharma 21
AVEO Pharma Amends Licensing Agreement with St. Vincent’s 22
Equity Offering 23
AVEO Pharma Prices Public Offering of Shares for USD5.7 Million 23
AVEO Pharma Raises USD6 Million in Public Offering of Shares upon Exercise of Warrants 25
AVEO Pharma Raises USD17.2 Million in Public Offering of Shares 26
Aveo Pharma Raises USD10.2 Million in Public Offering of Common Stock 27
Aveo Pharma Raises USD17 Million in Private Placement of Units 28
Aveo Pharma Completes Public Offering Of Shares For US$57.5 Million 30
AVEO Pharmaceuticals Inc – Key Competitors 31
AVEO Pharmaceuticals Inc – Key Employees 32
AVEO Pharmaceuticals Inc – Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Recent Developments 34
Financial Announcements 34
Aug 07, 2018: Aveo reports second quarter 2018 financial results and provides business update 34
May 08, 2018: AVEO Reports First Quarter 2018 Financial Results and Provides Business Update 36
Mar 13, 2018: AVEO Reports Full Year 2017 Financial Results and Provides Business Update 39
Nov 07, 2017: AVEO Reports Third Quarter 2017 Financial Results and Provides Business Update 42
Aug 09, 2017: AVEO Reports Second Quarter 2017 Financial Results and Provides Business Update 44
May 04, 2017: AVEO Reports First Quarter 2017 Financial Results and Provides Business Update 46
Mar 22, 2017: AVEO Reports Full Year 2016 Financial Results and Provides Business Update 48
Corporate Communications 50
Jun 15, 2018: AVEO Oncology added to the Russell 2000, Russell 3000, and Russell Microcap indexes 50
Nov 20, 2017: AVEO Announces Appointment of Nikhil Mehta, Ph.D., as Senior Vice President of Regulatory and Quality Assurance 51
May 16, 2017: AVEO Oncology appoints new CFO 52
Product News 53
09/13/2017: AVEO Oncology Announces Receipt of $0.5 million Payment from CANbridge 53
04/03/2017: AVEO Announces Milestone Payment from CANbridge for AV-203 54
Product Approvals 55
Aug 20, 2018: Development partner Boehringer Ingelheim supplies clinical material manufactured in China for new cancer drug 55
Aug 14, 2018: AVEO announces acceptance of CANbridge Investigational New Drug Application for CAN017 (AV-203) trial in esophageal squamous cell cancer (ESCC) in China 56
Dec 21, 2017: CANbridge Life Sciences Submits Investigational New Drug Application for CAN017 Trial in Esophageal Squamous Cell Cancer (ESCC) In China 57
Clinical Trials 58
Dec 07, 2017: AVEO Oncology Announces Clinical Update on Ficlatuzumab 58
Jun 05, 2017: AVEO Oncology and Biodesix Announce Results from Two Investigator-Sponsored Phase 1 Studies of HGF Targeted Antibody Ficlatuzumab at the 2017 ASCO Annual Meeting 59
Apr 20, 2017: AVEO To Provide Update on Pipeline Drug Ficlatuzumab at 2017 ASCO Annual Meeting 61
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62

List of Tables
AVEO Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
AVEO Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
AVEO Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
AVEO Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
AVEO Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
AVEO Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Aveo Pharma Amends Agreement With Biodesix For Ficlatuzumab 12
Aveo To Enter Into Co-Development Agreement For Lung Cancer Drug 14
National Comprehensive Cancer Enters Into Co-Development Agreement With AVEO Pharma And Astellas Pharma 15
CANbridge Life Sciences Enters into Licensing Agreement with AVEO Oncology 17
EUSA Pharma Exercises Option for Licensing Agreement with AVEO Pharma for TiNivo Combination Study 19
Novartis to Terminate Licensing Agreement with Aveo Pharma 21
AVEO Pharma Amends Licensing Agreement with St. Vincent’s 22
AVEO Pharma Prices Public Offering of Shares for USD5.7 Million 23
AVEO Pharma Raises USD6 Million in Public Offering of Shares upon Exercise of Warrants 25
AVEO Pharma Raises USD17.2 Million in Public Offering of Shares 26
Aveo Pharma Raises USD10.2 Million in Public Offering of Common Stock 27
Aveo Pharma Raises USD17 Million in Private Placement of Units 28
Aveo Pharma Completes Public Offering Of Shares For US$57.5 Million 30
AVEO Pharmaceuticals Inc, Key Competitors 31
AVEO Pharmaceuticals Inc, Key Employees 32
AVEO Pharmaceuticals Inc, Subsidiaries 33

List of Figures
AVEO Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
AVEO Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
AVEO Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
AVEO Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
AVEO Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
AVEO Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
AVEO Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
AVEO Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★調査レポート[AVEO Pharmaceuticals Inc (AVEO):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C9815)販売に関する免責事項を必ずご確認ください。
★調査レポート[AVEO Pharmaceuticals Inc (AVEO):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆